Throughout the last three months, 4 analysts have evaluated Cara Therapeutics (NASDAQ:CARA), offering a diverse set of opinions from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Cara Therapeutics, revealing an average target of $6.25, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 26.47% decrease from the previous average price target of $8.50.

Breaking Down Analyst Ratings: A Detailed Examination

The perception of Cara Therapeutics by financial experts is...